INTRODUCTION
Phasmapheresis has recently been employed in the treatment of myasthenia gravis (Behan et al., 1979; Dau et al., 1977; Pinching et al., 1976) . It has generally been reserved for more severely affected patients who have failed to respond to other forms of therapy. Improvement is usually temporary and therefore it has been combined with either steroids and/or immunosuppressive agents in the attempt to obtain long term benefit.
Circulating acetylcholine receptor (AChR) antibodies have been found in the serum of 90% patients with myasthenia gravis (Lindstrom et al., 1976) . They have been implicated in the pathogenesis of this disorder by passive transfer studies (Toyka et al., 1977) , in vitro degradation of receptors in myotube tissue culture , and by a myasthenic syndrome induced by monoclonal antibody directed to the AChR receptor (Lennon & Lambert, 1980) . Plasmapheresis is presumed to operate by removing a circulating humoral factor which is essential to the pathogenesis of myasthenia gravis (Newsom-Davis et al., 1978) . Clinical improvement has been reported to be associated with a reduction in the AChR antibody titer suggesting this may be the specific circulating factor (Newsom-Davis, et al., 1979) .
In our clinic, we have used plasmapheresis to prepare myasthenic patients for thymectomy. Anticholinesterase agents and steroids are avoided. If patients have already been started on medication prior to referral, attempts are made to discontinue them during plasmapheresis (Wechsler & Olanow, In Press) . Thymectomy is then performed by a sternal splitting approach. We attempt a total thymectomy by removing all mediastinal fat and searching carefully for any ectopic foci of thymic tissue (Wechsler & Olanow, 1980) . Post-operative medications are not employed, if possible. Clinical follow-up studies with serial AChR antibody levels have suggested that a thymic factor may be essential in the pathogenesis of myasthenia gravis (Olanow & Roses, in press (c) ). We have failed to demonstrate a direct correlation between the antibody titer and the clinical course of individual patients (Roses et al., In Press) . Furthermore, patients who have undergone thymectomy with no other therapy have shown dramatic improvement, but continue to maintain elevated AChR antibody levels (Olanow et al. (a) , In Press; Olanow et al. (b) , In Press).
While the majority of our patients became asymptomatic following early thymectomy, some had residual ocular dysfunction. Prior to the institution of any other medical therapy, plasmapheresis was performed in 5 patients with residual ocular dysfunction to determine whether a reduction in AChR antibody titer in this population would improve these signs. We report the failure of plasmapheresis to influence residual post-thymectomy dysfunction in any of these patients despite significant AChR antibody reduction.
MATERIAL AND METHODS
Five myasthenia gravis patients who had undergone previous thymectomy were entered into the study (Table I) . Diagnosis was based on clinical, electrical, pharmacological and serological criteria. Thymectomy was performed within 6 months of onset of symptoms. Each patient improved but had some persistent ocular dysfunction. Each was responsive to edrophonium chloride and was receiving no medication. Score Test
•Graded according to Osserman (1972) .
Plasmapheresis, using an IBM Cell Separator, was carried out 5 to 31 months following thymectomy. Three to 4 liters of plasma were removed per exchange and replaced isovolemically with 2-3% albumin in Ringer's lactate. Four to 11 procedures were performed on each patient. AChR antibody titers were serially measured using a radioimmunoassay technique with human antigen (McAdams & Roses, 1980) . AChR antibody titers were elevated in each case ranging from 0.194 to 14.8 nM (0.1 nM is diagnostic and greater than 1 nM is highly abnormal in our laboratory).
Following plasmapheresis, no medications were introduced during the subsequent 3 weeks. Thereafter, prednisone therapy in gradually increasing doses was begun. Ocular dysfunction was quantitated using a clinical grading system illustrated in Table II .
RESULTS
The results are summarized in Table   0 Figure I . Figure II represents the serial AChR antibody levels and the clinical response of a typical patient treated with plasmapheresis and subsequently prednisone. Clinical improvement was not associated with a reduction in the AChR antibody titer, and a reduction in the AChR antibody titer did not result in clinical improvement.
DISCUSSION
Five myasthenia gravis patients with residual ocular features following thymectomy failed to respond to plasmapheresis. These patients were receiving no other medical therapy. Subsequently, relatively small doses of prednisone resulted in striking ocular improvement in each patient.
Differences in the technique and timing of thymectomy, and in the management of drugs during the preand post-thymectomy stages, make it difficult to directly compare the effect of phasmapheresis on patients described in the literature with those we report who have been treated only with early thymectomy. Most studies of plasmapheresis have been performed on patients receiving concomitant steroids and/or immunosuppressive agents. While these medications cloud •Grading ol" ocular dysfunction as described in Table II . 
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Figure I -A comparison of the effects of plasmapheresis and prednisone on residual post-thymectomy ocular dysfunction. Ocular dysfunction is scored according to Table II . Osserman (1972) . Ocular dysfunction (Grade I) is further subdivided according to a scoring system outlined in Table II. an evaluation of the role of plasmapheresis, it seems likely that improvement is due to plasmapheresis, since when medications are employed alone benefit is relatively delayed (NewsomDavis, et al., 1979) . Many of the reported patients have also had thymectomies. They are, however, severely affected with myasthenia gravis and it is possible that the thymic influence was not totally eradicated, due to incomplete or delayed thymectomy. This might occur for the severity and progression of symptoms despite thymectomy and the subsequent beneficial effect of plasmapheresis. It is questioned whether plasmapheresis acts by removal of the AChR antibody. Despite a dramatic reduction in AChR antibody titer induced by plasmapheresis, no clinical improvement was detected in our patients. The possibility that there are subsets of antibodies to the AChR which are not currently detected, seems unlikely in view of the dramatic response to plasmapheresis we observe when preparing our patients for thymectomy. The possibility that the antibody may bind more tightly to the AChR of eye muscles and thus be less responsive to plasmapheresis is considered. More prolonged plasmapheresis theoretically may have led to some benefit. This also seems unlikely, however, since no such delay is noted in the response of the ocular features of myasthenia gravis to plasmapheresis prior to thymectomy.
The failure of a plasmapheresis induced reduction in the AChR antibody titer to improve postthymectomy ocular dysfunction suggests that plasmapheresis may operate by the removal of other factor(s), independent of or in addition to the AChR antibody. The beneficial effect of plasmapheresis prior to thymectomy suggests that these factor(s) may be of thymic origin. It is known that thymic-derived T-lymphocytes can regulate the intensity of virtually all immune reactions (Reinhez & Schlossman, 1980) . This study casts further doubt on the AChR antibody being the sole causative basis of myasthenia gravis and suggests that factors of thymic origin are of critical importance in the development of clinical symptoms. The mechanism by which prednisone operates is unknown but appears to be different than plasmapheresis.
